Study S001735

A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02713477
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 20
Start: 2016-04
Primary completion: 2016-06
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010; DRUG:Insulin glargine HOE901; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1176-6235

Registered primary outcomes

Measurement of plasma glucose concentrations [1 day (D1) in each treatment period]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013418	Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial. Inoue M, Diabetes, obesity & metabolism	2019	Randomized trial	PMID 31050109 DOI	registry reference RESULT:31050109